Skip to main content
Top
Published in: Diabetologia 5/2021

01-05-2021 | Insulins | Editorial

Celebrating 100 years of insulin

Author: Sally M. Marshall

Published in: Diabetologia | Issue 5/2021

Login to get access

Excerpt

Work in the University of Toronto (ON, Canada) during 1921 culminated in January 1922, when Leonard Thompson received his first injection of a purified pancreatic extract containing insulin. This remarkable event built on many years of ground-breaking scientific work by a number of individuals around the world, including Claude Bernard, Paul Langerhans, Oskar Minkowski, Joseph von Mering, Eugene Opie, Georg Ludwig Zülzer and Nicolas Paulesco, to name but a few. The unique achievements of the Toronto team, collaborating with industry, includes the speed at which they were able to purify, test and produce insulin in sufficient quantities for it to become a viable treatment for diabetes. These events have been described eloquently by Michael Bliss in his book: The Discovery of Insulin [1]. The immediate and long-term consequences of insulin therapy are life-changing for individuals with diabetes and continue to stimulate scientific research and learning. …
Literature
1.
go back to reference Bliss M (1982) The Discovery of Insulin. The University of Chicago Press, ChicagoCrossRef Bliss M (1982) The Discovery of Insulin. The University of Chicago Press, ChicagoCrossRef
Metadata
Title
Celebrating 100 years of insulin
Author
Sally M. Marshall
Publication date
01-05-2021
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 5/2021
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-021-05417-3

Other articles of this Issue 5/2021

Diabetologia 5/2021 Go to the issue

List of Referees

Referees 2020

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine